Wotton replaces Gilman as CEO of cell, gene therapy startup Obsidian

Obsidian CEO Paul Wotton (Business Wire)

Obsidian Therapeutics has named Paul Wotton as CEO. The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics.  

Under Gilman’s leadership, Obsidian broke cover with a $49.5 million series A round and went on to enter into a collaboration with Celgene. Obsidian attracted the strategic and financial interest on the strength of its efforts to use synthetic biology to improve the regulation of cell and gene therapies through the use of destabilizing domains and companion small-molecule medicines.

Now, Wotton will assume responsibility for taking the science forward. Wotton comes to Obsidian with 30 years of biopharma experience that includes stints as CEO of a clutch of biotechs.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

RELATED: Gilman buckles in as Arrakis raises $75M, gains momentum

Wotton was last seen leading Flagship Pioneering-backed Sigilon Therapeutics but stepped back from the role last year to manage a family health issue. Ex-Bioverativ EVP Rogerio Vivaldi stepped in to the Sigilon CEO role, leaving Wotton free to take up the post at Obsidian.

Earlier in his career, Wotton led Ocata Therapeutics to its drawn-out $379 million takeover by Astellas and served as CEO of Antares Pharma and Topigen Pharmaceuticals. 

Wotton’s resume is littered with companies active in areas that overlap with Obsidian’s focus on cell and gene therapy. Ocata landed the Astellas deal on the strength of its stem cell assets, while Sigilon is working on engineered human cells. That makes Wotton a good fit for Obsidian on paper. 

RELATED: Celgene strikes Obsidian deal to boost CAR-T options

“Paul’s substantial experience, his strategic business savvy, together with his in-depth of knowledge of cell and gene therapies make him a natural choice to lead the Obsidian team and advance its next generation cell and gene therapies into the clinic,” Gilman said in a statement.

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.